The mechanism of immune therapeutic response dependent on USP22 involves STAT1 stabilization via deubiquitination and promotes the FN-JAK1-STAT1 signal, which is a pathway involved in immune therapy resistance in melanoma [68]. This evidence concerns the gene STAT1 and melanoma.